Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024
Innate Pharma announces FDA clearance of the IND for IPH4502, a Nectin-4 ADC to be developed in solid tumors
Innate Pharma reports First Half 2024 Business Update and Financial Results
Monalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024
Innate Pharma announces conference call and webcast for first half 2024 financial results and business update
Innate Pharma announces its participation in the H.C. Wainwright 26th Annual Global Investment Conference
Innate Pharma announces its participation in upcoming investor conference
Number of shares and voting rights of Innate Pharma as of July 10, 2024
Number of shares and voting rights of Innate Pharma as of June 10, 2024
Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial
